Vitrolife Interim Report January -- June 2004
17 août 2004 03h25 HE
|
Vitrolife
STOCKHOLM, Sweden, Aug. 17, 2004 (PRIMEZONE) -- Vitrolife:
- Turnover increased by 13 percent, to SEK 55.1 million (48.8). Adjusted for currency effects the increase was 16 percent. During the...
Vitrolife Receives Patent Approval in USA
16 août 2004 03h19 HE
|
Vitrolife
STOCKHOLM, Sweden, Aug. 16, 2004 (PRIMEZONE) -- Vitrolife has been notified that the company's patent application, regarding the use of recombinant albumin with or without hyaluronic acid in media...
Vitrolife Products Receive European Approval
28 juin 2004 02h27 HE
|
Vitrolife
STOCKHOLM, Sweden, June 28, 2004 (PRIMEZONE) -- Vitrolife has received European approval (CE mark) for a complete series of products within ART (Assisted Reproductive Technology). "This gives us...
Anna Ahlberg New CFO at Vitrolife AB (publ)
22 juin 2004 09h54 HE
|
Vitrolife
STOCKHOLM, Sweden, June 22, 2004 (PRIMEZONE) -- Anna Ahlberg has been appointed as Head of Vitrolife's accounting and financing department and for investor relations.
Anna Ahlberg has worked within...
Vitrolife: Date of 2003 Year-End Report
02 févr. 2004 13h36 HE
|
Vitrolife
STOCKHOLM, Sweden, Feb. 2, 2004 (PRIMEZONE) -- Vitrolife's year end report for 2003 will be presented the 17th of February instead of the earlier date preliminary set (12th February) due to a change...
Vitrolife sells cross-linked hyalonic-acid subsidiaries for 7 million USD plus royalty to Mentor Corp., U.S.A.
26 août 2003 03h46 HE
|
Vitrolife
STOCKHOLM, Sweden, August 26, 2003 (PRIMEZONE) -- Vitrolife AB announced today that it has completed the sale of two of its subsidiaries, A-Life Ltd and A-Life Inc, to Mentor Corporation, a global...
Dr. Magnus Nilsson CEO of Vitrolife
13 août 2003 10h56 HE
|
Vitrolife
STOCKHOLM, Sweden, Aug. 13, 2003 (PRIMEZONE) -- The Board of Directors appointed Dr. Magnus Nilsson CEO of Vitrolife AB (publ). Magnus Nilsson was previously Acting CEO of Vitrolife since January 3,...
Vitrolife receives FDA marketing approval of EmbryoGlue -- a Breakthrough in ART (Assisted Reproductive Technology)
09 juil. 2003 08h23 HE
|
Vitrolife
STOCKHOLM, Sweden, July 9, 2003 (PRIMEZONE) -- The American Food and Drug Administration (FDA) has approved Vitrolife's application for market clearance, 510(k), for EmbryoGlue(R) developed in close...
Vitrolife launches EmbryoGlue -- A Breakthrough in ART (Assisted Reproductive Technology)
26 mai 2003 08h39 HE
|
Vitrolife
STOCKHOLM, Sweden, May 26, 2003 (PRIMEZONE) -- EmbryoGlue(R) is an implantation promoting medium for transfer of embryos back into the woman, with physical properties more similar to the uterine...
Vitrolife announces issuance of patent for new cell cryopreservation technique
10 mars 2003 12h46 HE
|
Vitrolife
STOCKHOLM, Sweden, March 10, 2003 (PRIMEZONE) -- Vitrolife (Stockholm:VITR) inventors have been granted a U.S. Patent for a new cryopreservation technique for viable cells, called loop vitrification....